Articles Archives
10/29/2025
Cryoport Systems Wins CPHI Pharma Award for Supply Chain Excellence
We are proud to announce that Cryoport Systems has been awarded the prestigious Supply Chain Excellence Award at the 2025 CPHI Pharma Awards, a recognition that celebrates innovation, impact, and leadership in pharmaceutical supply chain management. This honor reflects our unwavering commitment to transforming the way life-saving therapies are managed and delivered to patients across the globe.
10/28/2025
Built or Bought? Why Biotechs are Outsourcing Supply Chain Infrastructure
For companies developing advanced therapy medicinal products (ATMPs), building an in-house end-to-end supply chain may seem like the ultimate sign of maturity. But in today’s resource-constrained market, biotech leaders are increasingly asking themselves whether it’s better to build, or to buy. From startups operating on limited funding to global biopharma players scaling into new markets, outsourcing supply chain infrastructure is becoming more than just a cost saving tactic. By partnering with specialized providers, developers gain instant access to global networks, regulatory expertise and compliance, and technical capabilities that would take years and significant capital to build internally.
08/29/2025
The Hidden Risks in Your Supply Chain: How Regulatory Support Can Save Your CGT Program
The temperature-controlled supply chain has become so much more than a straightforward logistics function, especially for advanced therapies. It has quickly evolved into a critical extension of your manufacturing process, your clinical trials, and your path to commercialization. Every step, from sourcing raw materials to delivering the final drug product to patients, must operate within strict regulatory and quality parameters where even the smallest oversight can cascade into regulatory delays, product loss, or even compromised patient safety.
08/07/2025
Supporting the Health of Cats Worldwide and the Future of Veterinary Therapeutics
This International Cat Day, we celebrate our feline companions as we recognize the science and care that support their health. As veterinary medicine continues to evolve, so does the complexity of the treatments available. Biotherapeutics, advanced cell and gene therapies, and next-generation vaccines are changing the way veterinary professionals care for cats, particularly those living with chronic conditions or in need of specialized care. Behind the scenes, Cryoport Systems plays an important role in enabling this new era of treatment.
07/31/2025
Earning the Next Trial: How Supply Chain Strategy Helps CROs Build Sponsor Trust
Contract Research Organizations (CROs) play a critical role in the biopharmaceutical industry, often executing clinical trials on behalf of sponsors. They’re tasked with wide-ranging expectations that span numerous functions, including maintaining the balance of operational excellence against regulatory compliance and cost efficiency. This complexity is compounded when clinical trial sites grow to span the globe, additional therapeutic areas, and expanded client populations. In such a competitive market, it’s not enough to simply deliver results. CROs must also build trust.
07/29/2025
A Glimpse Inside the Future of ATMP Supply Chains: Alison Pritchard on the Beyond Biotech Podcast
In an industry where innovation moves fast but patient access often lags behind, how can we build supply chains that are not only compliant and efficient, but also flexible and ready to scale? That’s the question Alison Pritchard, Vice President of Business Development for Cryoport Systems, tackles in her recent interview with Beyond Biotech, the podcast from Labiotech.eu. Alison explores the state of the advanced therapy medicinal products (ATMP) market in 2025 and what it will take to meet the rising expectations of therapeutic developers, regulators, and – most importantly – patients.
07/28/2025
Turning Risk into Resilience with Supply Chain Resilience for CDMOs
Contract Development and Manufacturing Organizations (CDMOs) are under more pressure than ever to deliver reliable results in an unpredictable world. From geopolitical instability to material shortages to increasingly complex regulatory expectations, the risks facing clinical and commercial programs have intensified. For CDMOs, these risks don’t just affect their own operations, they directly impact their clients’ ability to bring therapies to patients.
07/25/2025
Scaling with Confidence for CDMO Supply Chain Alignment
Contract Development and Manufacturing Organizations (CDMOs) play a critical role in the life sciences industry, enabling biopharma innovators to bring new therapies from development to manufacturing to patients around the world. The demand placed on CDMOs has only increased in recent years, especially as cell, gene, and biologic therapies have moved from concept to clinic at unprecedented speeds. While the technical and scientific capabilities of CDMOs have advanced to meet these challenges, one area remains a frequent source of friction and delay...the end-to-end, temperature-controlled supply chain.
07/24/2025
